3666676652

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building

Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510



Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name			
American Psychiatric Association			
2. Address Check if different than previously reported		***************************************	······································
1000 Wilson Boulevard, Suite 1825			
Arlington	/A	22209	US
3. Principal place of business (if different than line 2)			······································
14:14:b:b:d:4:4:	ip or Country	*************************	
4a. Contact Name b. Telephone number	c, E-mail		5. Senate ID#
Ms. Therese Swetnam (703) 907-7305 tswe	tnam@psych.org		3151-12
7. Cheft Name			6. House ID#
American Psychiatric Association		***	3048900
10. Check if this is a Termination Report   □  □  □ Termination Date  INCOME OR EXPENSES - Complete Either Line 1			11. No Lobbying Acti
12. Lobbying Firms		13. Organ	izations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relat were:	ing to lobbying ac	stivities for this reporting
Less than \$10,000	Less than \$10,000		
\$10,000 or more	\$10,000 or more	☑ ⇒ \$	276,329
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).			cck box to indicate expe s for description of optic
	✓ Method A. Method B.		ts using LDA definitions of ts under section 6033(b)(8)
	☐ Method C.		ts under section 162(e) of t
		Senate Password	Edition S. Stelevil
Signature Therese M Swetnam  Options agreement to Southern and Date continued to Southern and So	eMercel Individual Date	8/10/2006	

Th. 1	Thomas Coulting	Object to occ
Printed Name and Title	i nerese Swetnam,	Uniet Financial Officer

Ö

✓ Page 1

-	
➂	

LD-2DS (Rev. 4.07)

	_m	
		,
3666076656		
300		

: American Psychiatric Association Registrant.Name	American Psychiatric Association Client Name
ADDENDUM for General Lobbying Issue Area	
16. Specific lobbying issues (continued from previous	us page)
Review Process for Adjudicating Initial Disability Clair	dministration Disability Determinations: Administrative ms, Titles II and XVI of the Social Security Act, S. 1950 ordability Act, Introduction of Senate mental health pass Act and Amendments of 2006 (AIDS health care)
	·
·	
·	
·	

LD-2DS

Page \_5\_

Page \_7

American Psychiatric Association Registrant Name Client	American Psychiatric Association Name
ADDENDUM for General Lobbying Issue Area MMM	·

16. Specific lobbying issues (continued from previous page)

H.R. 1946, Medicare Mental Health Modernization Act of 2005, H.R. 2356, Preserving Patient Access to Physicians Act of 2005 (Sustainable Growth Rate), H.R. 1447, Seniors Mental Health Access Improvement 2005, H.R. 5324, Seniors Mental Health Access Improvement Act of 2006 (coverage of Marriage and Famil Therapists and Mental Health Counselors under Medicare)

Medicare Mental Health Modernization Act of 2005, H.R. 1447, Seniors Mental Health Access Improvemen 2005, S. 1932, Deficit Reduction Act of 2005 (removing marriage and family therapist provision)

Notice of Proposed Rulemaking for Medicare Program: Revisions to Payment Policies Under the Physician Schedule for Calendar Year 2006; Title XVIII, Section 1848 of the Social Security Act

Notice of Proposed Rulemaking for Medicare Program: Medicare Payments for Inpatient Psychiatric Facilitic Title XVIII, Section 1886(d) of the Social Security Act

Notice of Proposed Rulemaking for Medicare Program: HIPAA Administrative Simplification: Standards for Electronic Health Care Claims Attachments; Title II, Subtitle F of the Health Insurance Portability and Accountability Act of 1996; Title XI, Subpart C, Sections 1171 through 1179 of the Social Security Act

Notice of Proposed Rulemaking for Medicare Program: Termination of Non-Random Prepayment Review; 1 Sections 1874A and 934 of the Medicare Prescription Drug, Improvement and Modernization Act of 2003

Notice of Proposed Rulemaking for Medicare Program: Physicians' Referrals to Health Care Entities With W They Have Financial Relationships; Exceptions for Certain Electronic Prescribing and Electronic Health Rec Arrangements; Title XVIII, Section 1877 of the Social Security Act; and Title I, Sections 101 and 1860D of the Medicare Prescription Drug, Improvement and Modernization Act of 2003

Notice of Proposed Rulemaking for Medicare Program: Medicare and State Health Care Programs: Fraud a Abuse; Safe Harbor for Certain Electronic Prescribing Arrangements Under the Anti-Kickback Statute; Title Section 1128B(b)(3)(E) of the Social Security Act; and Title I, Sections 101 and 1860D of the Medicare Prescription Drug, Improvement and Modernization Act of 2003

Notice of Proposed Rulemaking and Notice of Interim Final Rule for Medicare Program: Competitive Acquisi Program (CAP) for Drugs and Biologicals, under Part B; Title XVIII, Sections 1861(s)(2)(A) and 1847B of the Social Security Act; and Title I, Section 303(d)of the Medicare Prescription Drug, Improvement and Moderni Act of 2003

Notice of Final Rulemaking for Medicare Program: Medicare Program; Revisions to Payment Policies Under Physician Fee Schedule for Calendar Year 2006 and Certain Provisions Related to the Competitive Acquisit Program of Outpatient Drugs and Biologicals under Part B; Title XVIII, Section 1848 of the Social Security A Title XVIII, Sections 1861(s)(2)(A) and 1847B of the Social Security Act; and Title I, Section 303(d)of the Me Prescription Drug, Improvement and Modernization Act of 2003

Notice Requesting Comments to Proposed Revisions for Medicare Program: U.S. Pharmacopeia's Draft Mo Guidelines, Version 2.0; Title I, Sections 101 and 1860D of the Medicare Prescription Drug, Improvement ar Modernization Act of 2003

Ç	Ç
( ا	Ó
¢	Ċ
Ç	כ
۲	٠,,,
Ç	Ç
Ç	Ç
¢	Ç
	C
è	*

) 
 e III, 03
rospe cial S
ans'
Med

LD-2DS

Page \_\_11

M
(0)
$\bigcirc$
14
$\mathbb{C}$
$\bigcirc$
C)
C

American Psychiatric Association Registrant Name	American Psychiatric Association Client Name
ADDENDUM for General Lobbying Issue Are	a LAW_
16. Specific lobbying issues (continued from prev	ious page)
Notices of Meetings for the EMTALA Technical Ad 1867 of the Social Security Act; and Section 10(a)	lvisory Group (TAG); Sections 1866(a)(1)(l), 1866(a)(1)(l) of the Federal Advisory Committee Act
Notice Requesting Comments to Pennsylvania dra 28. HEALTH AND SAFETY, PART IV. HEALTH C. B., CHAPTERS 101, 103, 105, 107	aft state regulations for hospitals and outpatient facilities; ARE FACILITIES, SUBPART A., CHAPTER 54; and SU
Notice of Meeting for the FDA Drug Safety and Ris Federal Advisory Committee Act	sk Management Advisory Committee; Section 10(a) of th
Notice of Proposed Rulemaking for Medicare Prog Sections 1874A and 934 of the Medicare Prescript	ram: Termination of Non-Random Prepayment Review; ion Drug, Improvement and Modernization Act of 2003
I ney have Financial Relationships; Exceptions for	ram: Physicians' Referrals to Health Care Entities With Note Certain Electronic Prescribing and Electronic Health Resial Security Act; and Title I, Sections 101 and 1860D of the dernization Act of 2003
Abuse; Sate Harbor for Certain Electronic Prescrib	ram: Medicare and State Health Care Programs: Fraud a ing Arrangements Under the Anti-Kickback Statute; Title and Title I, Sections 101 and 1860D of the Medicare n Act of 2003
Other Health Care Practitioners: Reporting on Advi Health Care Quality Improvement Act of 1986; Title	itioner Data Bank for Adverse Information on Physicians erse and Negative Actions; Title IV, Sections 401-432 of EXI, Section 1921 of the Social Security Act, as amende d Program Protection Act of 1987, and as amended by t
	· · · · · · · · · · · · · · · · · · ·

Add page to continue specific issues description for this i

LD-2DS

Page \_12\_

19. Interest of each foreign entity in the specific issues listed on line 16 above | Check if None

Page \_\_13

M
LO
$\bigcirc$
Ć
, and
O
$\Box$
C
C
700

American Psychiatric Association Registrant Name	American Psychiatric Association Client Name
ADDENDUM for General Lobbying Issue Area	
16. Specific lobbying issues (continued from previ	ious page)
Dept. of Defense Authorization, TRICARE provision	Physicians' Services Act of 2005, H.R. 3151, to remove tage under the Medicare prescription drug program, S. 27 ns, White House Conference on Aging, S. 3570, mendments of 2006, H.R. 2629, Positive Aging Act of 20
Notices of Meetings for the EMTALA Technical Advanced 1867 of the Social Security Act; and Section 10(a)	visory Group (TAG); Sections 1866(a)(1)(I), 1866(a)(1)(Note the Federal Advisory Committee Act
Notice Requesting Comments to Pennsylvania dra 28. HEALTH AND SAFETY, PART IV. HEALTH CA B., CHAPTERS 101, 103, 105, 107	ft state regulations for hospitals and outpatient facilities; ARE FACILITIES, SUBPART A., CHAPTER 54; and SUE
•	
	·
	·

LD-2DS

Page <u>14</u>

Page \_\_15

_
۳.,
Φ
$\Box$
C
P+104
75
C
6
C
~
O
O
A SHAPE

Registrant Name	American Psychiatric Association	Client Name	American Psychiatric Association
ADDENDUM	for General Lobbying Issue Area	PHA	
16. Specific lo	bbying issues (continued from previous	us page)	
- Frogram (C	oposed Rulemaking and Notice of Interin AP) for Drugs and Biologicals, under Par rity Act; and Title I, Section 303(d)of the	t B: Title XVIII. Se	ctions 1861/s)(2)(A) and 1847B of th
Program of Title XVIII, S	nal Rulemaking for Medicare Program: Mee Schedule for Calendar Year 2006 and Outpatient Drugs and Biologicals under F Sections 1861(s)(2)(A) and 1847B of the S Drug, Improvement and Modernization A	Certain Provision Part B; Title XVIII, Social Security Ac	s Related to the Competitive Acquis
Guidelines,	esting Comments to Proposed Revisions Version 2.0; Title I, Sections 101 and 186 on Act of 2003	s for Medicare Pro 60D of the Medica	gram: U.S. Pharmacopeia's Draft M re Prescription Drug, Improvement a
Notice of Me Federal Adv	eeting for the FDA Drug Safety and Risk I isory Committee Act	Management Advi	sory Committee; Section 10(a) of the
Sought relea	use of information from the Centers for Mexceptions and appeals processes in the	edicare and Medio Part D program	caid Services on Part D drug plans'
Sought relea	ise of information from the Centers for Mo Il formulary to improve classification of dr	edicare and Medic ugs used in the tre	caid Services on plans to revise Med eatment of addictive disorders
	•		

Ö / LD-2DS

Page <u>16</u>

Page \_\_17

American Psychiatric Association

Client Name

Notice Requesting Comments on International Drug Scheduling: Convention on Psychotropic Substance Convention on Narcotic Drugs; Butorphanol; Delta–9–tetrahydrocannabinol (Dronabinol); Gamma-Hydro Acid; Ketamine; Khat; Tramadol; Zopiclone; Buprenorphine; Oripavine; Title II of the Comprehensive Dru Prevention and Control Act of 1970; Single Convention on Narcotic Drugs, 1961; and 1971 Convention o Psychotropic Substances								
			,					
							ł	
					Page 35 of 46			

American Psychiatric Association

ADDENDUM for General Lobbying Issue Area ALC

Registrant Name

LD-2DS

Page <u>18</u>

Page \_\_19\_

Ö

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each contact the second selection of the client during the reporting period.

American Psychiatric Association

(one per page)

Registrant Name American Psychiatric Association

15. General issue area code

16. Specific lobbying issues

information as requested. Attach additional page(s) as needed.

AER - Aerospace

Therese Swetnem, Chief Financial Officer Filing #40695957-a29b-4d1f-a894-ecbf13a57e9a - Page 45 of 46 000

D-2DS (REV. 4.07)